Literature DB >> 26243714

Update on prolactinomas. Part 2: Treatment and management strategies.

Anni Wong1, Jean Anderson Eloy2, William T Couldwell3, James K Liu4.   

Abstract

The authors present an update on the various treatment modalities and discuss management strategies for prolactinomas. Prolactinomas are the most common type of functional pituitary tumor. Effective hyperprolactinemia treatment is of great importance, due to its potential deleterious effects including infertility, gonadal dysfunction and osteoporosis. Dopamine agonist therapy is the first line of treatment for prolactinomas because of its effectiveness in normalizing serum prolactin levels and shrinking tumor size. Though withdrawal of dopamine agonist treatment is safe and may be implemented following certain recommendations, recurrence of disease after cessation of the drug occurs in a substantial proportion of patients. Concerns regarding the safety of dopamine agonists have been raised, but its safety profile remains high, allowing its use during pregnancy. Surgery is typically indicated for patients who are resistant to medical therapy or intolerant of its adverse side effects, or are experiencing progressive tumor growth. Surgical resection can also be considered as a primary treatment for those with smaller focal tumors where a biochemical cure can be expected as an alternative to lifelong dopamine agonist treatment. Stereotactic radiosurgery also serves as an option for those refractory to medical and surgical therapy.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bromocriptine; Cabergoline; Dopamine agonist; Endoscopic endonasal transsphenoidal surgery; Pituitary tumor; Prolactinomas; Radiosurgery

Mesh:

Substances:

Year:  2015        PMID: 26243714     DOI: 10.1016/j.jocn.2015.03.059

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  19 in total

1.  A combined opiate agonist and antagonist treatment reduces prolactin secreting pituitary tumor growth.

Authors:  George Maglakelidze; Olivia Wynne; Dipak K Sarkar
Journal:  J Cell Commun Signal       Date:  2017-01-31       Impact factor: 5.782

Review 2.  Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review.

Authors:  Tomáš Česák; Pavel Poczos; Jaroslav Adamkov; Jiří Náhlovský; Petra Kašparová; Filip Gabalec; Petr Čelakovský; Ondrej Choutka
Journal:  Pituitary       Date:  2018-12       Impact factor: 4.107

Review 3.  The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.

Authors:  M Victoria Recouvreux; M Andrea Camilletti; Daniel B Rifkin; Graciela Díaz-Torga
Journal:  J Endocrinol       Date:  2015-12-23       Impact factor: 4.286

4.  The role of endoscopic endonasal surgery in the management of prolactinomas based on their invasiveness into the cavernous sinus.

Authors:  Hussam Abou-Al-Shaar; Arka N Mallela; Aneek Patel; Rimsha K Shariff; Samuel S Shin; Phillip A Choi; Amir H Faraji; Pouneh K Fazeli; Tina Costacou; Eric W Wang; Juan C Fernandez-Miranda; Carl H Snyderman; Paul A Gardner; Georgios A Zenonos
Journal:  Pituitary       Date:  2022-04-25       Impact factor: 4.107

5.  Role of prolactin/adenoma maximum diameter and prolactin/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas.

Authors:  Yinxing Huang; Chenyu Ding; Fangfang Zhang; Deyong Xiao; Lin Zhao; Shousen Wang
Journal:  Oncol Lett       Date:  2017-11-21       Impact factor: 2.967

6.  High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?

Authors:  Etual Espinosa-Cárdenas; Miriam Sánchez-García; Claudia Ramírez-Rentería; Victoria Mendoza-Zubieta; Ernesto Sosa-Eroza; Moises Mercado
Journal:  Endocrine       Date:  2020-06-17       Impact factor: 3.633

7.  Surgical treatment for male prolactinoma: A retrospective study of 184 cases.

Authors:  Yi-Jun Song; Mei-Ting Chen; Wei Lian; Bing Xing; Yong Yao; Ming Feng; Ren-Zhi Wang
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

8.  Group B Streptococcus Meningitis Presenting as the Initial Symptom of a Recurrent Pituitary Adenoma.

Authors:  Kyung Wook Kang; Byung Hyun Baek; Sang Hoon Kim; Hyun Soo Kim; Tai Seung Nam; Sang Chul Lim; Myeong Kyu Kim
Journal:  J Clin Neurol       Date:  2017-10-31       Impact factor: 3.077

9.  The Chance of Permanent Cure for Micro- and Macroprolactinomas, Medication or Surgery? A Systematic Review and Meta-Analysis.

Authors:  Qianquan Ma; Jun Su; Ying Li; Jiaxing Wang; Wenyong Long; Mei Luo; Qing Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-25       Impact factor: 5.555

10.  Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery.

Authors:  Grzegorz Zielinski; Marcin Ozdarski; Maria Maksymowicz; Katarzyna Szamotulska; Przemysław Witek
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-07       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.